A European industrial group had identified a strategically valuable acquisition target in China. The combined entity would hold a meaningful share of its product segment in the Chinese market. The deal looked straightforward on paper. In practice, the buyer faced a layered approval regime, a compressed timeline, and a share purchase agreement (SPA) that had been drafted without reference to Chinese closing conditions. Missing the window would have meant losing a competitively priced asset to a domestic bidder already in the process.
M&A transactions in China involving foreign acquirers require mandatory competition clearance from the Shichang Jiandu Guanli Zongju (State Administration for Market Regulation. Alternatively. SAMR) when prescribed merger thresholds are met, alongside a parallel review under foreign investment legislation. The SPA must incorporate conditions precedent that reflect both SAMR approval timelines and any State Council oversight requirements. Failure to sequence these conditions correctly can void the transaction or expose the buyer to significant regulatory penalties.
This case study outlines how our team structured the legal strategy, managed the regulatory sequence. Additionally. Addressed complications that arose during the clearance process. offering three transferable lessons for cross-border acquirers considering similar transactions in China.
Client profile and the challenge at hand
The client was a mid-sized European manufacturing group with no prior presence in China. The target was a Waihuan Touzi Qiye – a wholly foreign-owned enterprise (WFOE) – operating in a sector subject to both competition review and restricted foreign investment categories. The buyer had signed a term sheet and was working toward a binding SPA within a tight window agreed with the seller.
Three challenges compounded each other. First, the deal exceeded the turnover thresholds that trigger mandatory merger notification to SAMR under China's competition legislation. Second, the target's business touched a sector listed under China's foreign investment catalogue, requiring a separate foreign investment review alongside the competition filing. Third, the original SPA draft had been prepared under English law and contained closing conditions that did not map onto Chinese regulatory timelines. The representations and warranties provisions assumed a 30-day closing period – workable in a European context, but incompatible with a Chinese regulatory review that can extend considerably longer.
Our engagement began after the term sheet was signed but before the SPA was executed. The opportunity to restructure the deal documents was still open. Losing that window – by executing the SPA before correcting the closing conditions – would have created a binding obligation to close on terms the buyer could not legally meet.
Our M&A advisory work for foreign acquirers entering China is described in more detail in our M&A transactions practice for China.
Legal strategy and key milestones
The strategy rested on three parallel workstreams, sequenced to avoid any gap between regulatory requirements and contractual obligations.
Workstream one – SPA restructuring. We revised the closing conditions to build in a realistic SAMR review period as a condition precedent. The representations and warranties were reframed to survive the extended pre-closing period. We also inserted a regulatory long-stop date that gave both parties a clear termination right if clearance was not obtained within an agreed maximum period. This protected the buyer from being indefinitely committed to a deal that regulators might delay or condition.
Workstream two – SAMR notification preparation. China's competition legislation requires the filing party to submit detailed information on market share, competitive overlap, and the combined entity's effect on the relevant market. We worked with the client's commercial team to define the relevant product and geographic markets accurately. Overstating competitive overlap would have invited a Phase II review; understating it risked a rejection for incomplete filing. The filing was submitted within two weeks of SPA execution.
Workstream three – foreign investment review coordination. Given the target's sector classification, we coordinated a parallel submission to the relevant authority under foreign investment legislation. This required a separate set of documents from the competition filing and operated on a different timeline. Mapping the two review tracks against each other – and against the SPA long-stop date – was critical to keeping the deal alive.
SAMR completed its initial review within the standard Phase I period and requested supplementary information on one market definition point. We responded within five business days. Clearance was granted without conditions shortly after. The foreign investment review concluded within a comparable timeframe. The SPA closed without triggering the long-stop provision.
For the corporate governance aspects of the post-closing integration, our team also drew on the firm's corporate law practice in China, particularly around WFOE restructuring and board composition requirements.
Complications and how they were resolved
The most significant complication arose during due diligence. A review of the target's historical contracts revealed an undisclosed revenue-sharing arrangement with a domestic distributor. The arrangement had characteristics that, under Chinese competition legislation, could be read as a resale price maintenance arrangement. This exposed the target – and potentially the acquirer post-closing – to regulatory risk under competition enforcement rules.
We addressed this in two ways. First, we introduced a specific representation and warranty into the SPA requiring the seller to confirm the absence of any ongoing arrangements that could constitute a competition law violation. Second, we structured an indemnity provision that would survive closing and cover any regulatory fine or enforcement action arising from pre-closing conduct. The seller accepted both amendments after brief negotiation.
A secondary complication involved the dispute resolution clause. The original SPA provided for arbitration before the China International Economic and Trade Arbitration Commission (CIETAC) seated in Beijing. This is a well-regarded institution and an appropriate choice for disputes arising from the Chinese law elements of the deal. However, the buyer's preference – consistent with its group policy – was for a neutral offshore seat. We negotiated a bifurcated clause: Chinese law issues to be resolved at CIETAC, and all other disputes under the governing law of the agreement at a neutral international seat. This compromise preserved the seller's preference for domestic arbitration on local law matters while giving the buyer access to an internationally enforceable award for financial claims.
For a comparable case involving a similarly structured regulatory and competition clearance process in a different high-growth market, see our M&A transaction case study for the UAE.
To explore how a similar legal strategy could apply to your acquisition in China, contact us at info@ferrazwhitmore.com.
Three transferable lessons
Lesson one – sequence the SPA around the regulatory timeline, not the other way around. Chinese M&A transactions involving foreign buyers frequently require multiple regulatory approvals running on different clocks. A closing condition that assumes a short pre-closing period will either force a breach or require a costly amendment after execution. Building a realistic long-stop date and a clearly defined condition precedent structure into the SPA before signing is far less expensive than renegotiating after the fact.
Lesson two – due diligence must include a competition compliance review of the target's existing commercial arrangements. SAMR's merger review assesses forward-looking competitive effects. But enforcement risk also runs backward: if the target has historical arrangements that raise competition concerns, those risks transfer to the acquirer at closing unless specifically carved out. A thorough review of the target's distribution, pricing, and exclusivity arrangements – as part of standard due diligence – should be non-negotiable in any Chinese inbound acquisition.
Lesson three – dispute resolution architecture matters as much as substantive law. Acquirers often accept boilerplate arbitration clauses without considering whether they align with the governing law of the transaction and the practical enforceability of any award. A CIETAC clause is appropriate for disputes governed by Chinese law and arising in China. For cross-border financial claims – where assets may sit in multiple jurisdictions – an offshore seat with recognised enforcement credentials provides materially stronger protection. The two needs are not mutually exclusive, as this matter demonstrated.
About Ferraz & Whitmore
Ferraz & Whitmore is an international law firm based in Lisbon, advising business clients across 46 jurisdictions. Our team combines Portuguese civil law expertise with English common law tradition to deliver cross-border legal solutions in M&A transactions and competition clearance matters, including complex inbound acquisitions in China. We act for international entrepreneurs, institutional investors, and in-house legal teams who need a lawyer in China matters guided by practitioners with real cross-border experience. As a law firm with deep Asia-Pacific coverage, we support clients from initial due diligence through SPA negotiation, SAMR filing, and post-closing integration. Our M&A team has advised on share purchase agreement structures across both civil law and common law systems, and has direct experience before CIETAC and other international arbitral bodies. To discuss your acquisition strategy in China, reach out to us at info@ferrazwhitmore.com.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.